Somewhat Positive Media Coverage Somewhat Unlikely to Impact Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
Headlines about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.2446082141296 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 1.13% during mid-day trading on Friday, hitting $59.44. The stock had a trading volume of 229,373 shares. Ultragenyx Pharmaceutical has a 12 month low of $51.67 and a 12 month high of $91.35. The stock’s 50-day moving average is $64.97 and its 200 day moving average is $67.17. The firm’s market cap is $2.52 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the firm earned ($1.46) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical will post ($7.24) earnings per share for the current fiscal year.
RARE has been the subject of a number of analyst reports. HC Wainwright lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $88.00 to $72.00 in a report on Wednesday, April 19th. Jefferies Group LLC upped their target price on Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the stock a “hold” rating in a report on Monday, May 8th. SunTrust Banks, Inc. upped their target price on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, Wedbush lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $80.00 to $75.00 in a report on Wednesday, April 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $84.87.
In other news, VP Theodore Alan Huizenga sold 480 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, May 26th. The shares were sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the sale, the vice president now directly owns 9,366 shares of the company’s stock, valued at approximately $538,170.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.20% of the stock is currently owned by insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.